WoundReference improves clinical decisions
 Choose the role that best describes you
Deutsch CJ, Tan A, Smailes S, Dziewulski P, et al.
Burns : journal of the International Society for Burn Injuries. Date of publication 2018 Aug 1;volume 44(5):1040-1051.
1. Burns. 2018 Aug;44(5):1040-1051. doi: 10.1016/j.burns.2017.11.013. The diagnosis and management of inhalation injury: An evidence based approach. Deutsch CJ(1), Tan A(2), Smailes S(3), Dziewulski P(2). Author information: (1)St. Andrew's Centre for Plastic Surgery and Burns, Chelmsford, United Kingdom. Electronic address: christopher.deutsch@doctors.org.uk. (2)St. Andrew's Centre for Plastic Surgery and Burns, Chelmsford, United Kingdom; StAAR Research Unit, Faculty of Medical Sciences, Anglia Ruskin University, 1-2 Bishop Hall Lane, CM1 1SQ, Chelmsford, United Kingdom. (3)St. Andrew's Centre for Plastic Surgery and Burns, Chelmsford, United Kingdom. INTRODUCTION: Smoke inhalation injury (II) is an independent risk factor for mortality in burns and its management is inherently complex. We aim to make recommendations for best practice in managing II and its sequelae by reviewing all available current evidence in order to provide an evidence-based approach. METHODS: We conducted a systematic search of the Cochrane database and Embase using PRISMA guidelines with no patient population exclusion criteria. Published work was reviewed and evidence levels graded. RESULTS: We identified 521 abstracts for inclusion. Of the 84 articles identified for secondary review, 28 papers were excluded leaving 56 papers suitable for final inclusion. CONCLUSIONS: We are able to identify a number of strategies in both diagnosis and treatment of II that have support in the published literature, including the role of bronchoscopy, permissive hypercapnia, nebulized heparin and hydroxycobalamin. Other strategies have not been shown to be harmful, but their efficacy is also not firmly established, such as high frequency oscillatory ventilation and exogenous surfactant. Prophylactic antibiotics and corticosteroids are not recommended. In general, published evidence for II is mostly Level 3 or below, due to a noticeable lack of large-scale human studies. This represents a challenge for evidence-based burns practice as a whole. Copyright © 2017 Elsevier Ltd and ISBI. All rights reserved. DOI: 10.1016/j.burns.2017.11.013 PMID: 29398078
Appears in following Topics:
Acute Burns - Introduction and Assessment
Acute Burns - Treatment